Bird flu vaccine on tap from Sanofi-Aventis

10th November 2005, Comments 0 comments

PARIS, Nov 10 (AFP) - French pharmaceutical group Sanofi-Aventis said Thursday it has agreed to produce 1.4 million doses of a prototype vaccine for humans to treat the strain of bird flu known as H5N1 which has killed more than 60 people in Asia.

PARIS, Nov 10 (AFP) - French pharmaceutical group Sanofi-Aventis said Thursday it has agreed to produce 1.4 million doses of a prototype vaccine for humans to treat the strain of bird flu known as H5N1 which has killed more than 60 people in Asia.

A spokesman for the company said the deal was signed with the country's health ministry to produce the "pre-pandemic" or "prototype" vaccine before the end of the year.

The company also said it would supply "up to 28 million vaccination doses if a pandemic was declared, once the virus that caused the pandemic was identified."

Sanofi-Aventis said last month it was developing a vaccine to treat H5N1, and had conducted a clinical trial this summer on 400 people aged between 18 and 60 years old.

Health experts fear the deadly H5N1 virus, which currently humans contract only after close exposure to birds and is not transmissible between people, could jump the species barrier to mix with common flu genes and spark a worldwide pandemic.

Copyright AFP

Subject: French news

0 Comments To This Article